Search

Your search keyword '"Berry, John S."' showing total 118 results

Search Constraints

Start Over You searched for: Author "Berry, John S." Remove constraint Author: "Berry, John S."
118 results on '"Berry, John S."'

Search Results

1. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

5. Student Connections of Linear Algebra Concepts: An Analysis of Concept Maps

6. Using Technology to Facilitate Reasoning: Lifting the Fog from Linear Algebra

7. A Case Study of the Issues Arising when Teachers Adopt the Use of a New Form of Technology in Their Teaching for the First Time

8. Your Students' Images of Mathematicians and Mathematics.

13. Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients

15. Abstract CT150: Initial analysis of open-label administration of autologous tumor lysate (TL) + dendritic cells (DC) vaccine (TLPLDC) in melanoma patients who recurred during a phase IIb adjuvant vaccine trial

16. A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.

18. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

19. Abstract CT162: Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients

20. Abstract CT036: Early trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in ovarian cancer patients

21. A novel cancer vaccine platform utilizing autologous tumor lysate loaded into capped yeast cell wall particles.

23. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

24. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

25. Abstract B007: Improved disease-free survival in endometrial and ovarian cancer patients with low folate binding protein expression after treatment with the E39 peptide vaccine in a Phase I/IIa trial

26. Phase Ib Trial Comparing Different Doses and Schedules of a Folate-Binding Protein-Derived Peptide Vaccine, E39, and its Attenuated Version, E39’, to Induce Long-Term Folate-Binding Protein-Specific Immunity in Disease-Free Cancer Patients

27. Abstract CT073: Comparing an attenuated booster (E39’) vs E39 booster to potentiate the clinical benefit of the folate binding protein (FBP)-derived vaccine (E39 + GM-CSF) in a phase I/IIa trial to prevent recurrence in endometrial (EC) and ovarian cancer (OC) patients

28. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.

29. The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 + GM-CSF in ovarian and endometrial cancer patients to prevent recurrence.

30. Analysis of Clinical and Pathologic Factors of Pure, Flat Epithelial Atypia on Core Needle Biopsy to Aid in the Decision of Excision or Observation

33. Correlation between Robust Local Reactions Prompting GM-CSF Dose Reduction to Clinical Response in a Phase II Trial of the GP2+GM-CSF HER2 Peptide Vaccine to Prevent Breast Cancer Recurrence

34. Abstract CT209: Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of the AE37+GM-CSF HER2 peptide vaccine

35. Preliminary results of the phase I/IIa dose finding trial of a folate binding protein vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence.

36. Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.

37. Abstract OT3-1-09: Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence

38. The Noninvasive Carbon Dioxide Gradient (NICO2G) during Hemorrhagic Shock

39. Venous Thromboembolism during Combat Operations: A 10-y Review

41. Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence

43. Abstract 2558: HLA-A2 and HER2 expression levels as clinical prognostic factors in breast cancer patients: implications for peptide cancer vaccine trials

44. Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

46. Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy.

47. Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.

48. Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy.

50. Vaccine-specific T-cell proliferation in response to a dual peptide cancer vaccine in breast and ovarian cancer patients

Catalog

Books, media, physical & digital resources